BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Rating Lowered by Royal Bank Of Canada
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) was downgraded by analysts at Royal Bank Of Canada from an “outperform” rating to a “sector perform” rating in a research note issued on Thursday, Marketbeat reports. They currently have a $11.00 price target on the biotechnology company’s stock. Royal Bank Of Canada’s price target points to a […]
10 Sep 13:06 · The Markets Daily